ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapy

International Journal of Radiation Oncology Biology Physics

Volumn 64, Issue 1, 2006, Pages 33-37

  Frederick, Barbara ^a   Gustafson, Dan ^b   Bianco, Cataldo ^c   Ciardiello, Fortunato ^d   Dimery, Isaiah ^e   Raben, David ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PISA   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e ASTRAZENECA   (United Kingdom)

Author keywords

Angiogenesis; Radiotherapy; Tyrosine kinase inhibitor; Vascular endothelial growth factor receptor

Indexed keywords

DRUG THERAPY; ENZYME INHIBITION; GROWTH KINETICS; PHARMACOKINETICS; RADIOTHERAPY; TUMORS;

ANGIOGENESIS; TUMOR PROGRESSIONS; TYROSINE KINASE INHIBITOR; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR;

ENZYME KINETICS;

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; N ACETYLCOLCHINOL PHOSPHATE; PROTEIN TYROSINE KINASE; VANDETANIB; VASCULOTROPIN;

CANCER; CANCER CONTROL; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG HALF LIFE; ENZYME ACTIVITY; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANGIOGENESIS INHIBITORS; ANIMALS; COMBINED MODALITY THERAPY; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PIPERIDINES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 29244461412     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2005.05.050     Document Type: Conference Paper

References (38)

1. S.R. Wedge, D.J. Ogilvie, M. Dukes ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration Cancer Res 62 2002 4645 4655
2. F.A. Eskens Angiogenesis inhibitors in clinical development Where are we now and where are we going? Br J Cancer 90 2004 1 7
3. J. Folkman Tumor angiogenesis Therapeutic implications N Engl J Med 285 1971 1182 1186
4. N. Ferrara, T. Davis-Smyth The biology of vascular endothelial growth factor Endocr Rev 18 1997 4 25
5. A. Abdollahi, K.E. Lipson, X. Han SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro Cancer Res 63 2003 3755 3763
6. D.H. Gorski, M.A. Beckett, N.T. Jaskowiak Blockade of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation Cancer Res 59 1999 3374 3378
7. H.H. Steiner, S. Karcher, M.M. Mueller Autocrine pathways of the vascular endothelial growth factor (VEGF) in glioblastoma multiforme Clinical relevance of radiation-induced increase of VEGF levels J Neurooncol 66 2004 129 138
8. M.I. Koukourakis, A. Giatromanolaki, E. Sivridis Squamous cell head and neck cancer Evidence of angiogenic regeneration during radiotherapy Anticancer Res 21 2001 4301 4309
9. D. Fukumura, T. Gohongi, A. Kadambi Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability Proc Natl Acad Sci USA 98 2001 2604 2609
10. P. Sonveaux, A. Brouet, X. Havaux Irradiation-induced angiogenesis through the up-regulation of the nitric oxide pathway Implications for tumor radiotherapy Cancer Res 63 2003 1012 1019
11. C.G. Lee, M. Heijn, E. di Tomaso Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions Cancer Res 60 2000 5565 5570
12. L. Geng, E. Donnelly, G. McMahon Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy Cancer Res 61 2001 2413 2419
13. S. Ning, D. Laird, J.M. Cherrington The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation Radiat Res 157 2002 45 51
14. R.J. Griffin, B.W. Williams, R. Wild Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response Cancer Res 62 2002 1702 1706
15. B.A. Teicher, S.A. Holden, G. Ara Influence of an anti-angiogenic treatment on 9L gliosarcoma oxygenation and response to cytotoxic therapy Int J Cancer 61 1995 732 737
16. R.T. Tong, Y. Boucher, S.V. Kozin Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors Cancer Res 64 2004 3731 3736
17. R.K. Jain Normalization of tumor vasculature An emerging concept in antiangiogenic therapy Science 307 2005 58 62
18. P. Wachsberger, R. Burd, A.P. Dicker Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents Exploring mechanisms of interaction Clin Cancer Res 9 2003 1957 1971
19. P.M. Harari Epidermal growth factor receptor inhibition strategies in oncology Endocr Relat Cancer 11 2004 689 708
20. J.S. Park, L. Qiao, Z.Z. Su Ionizing radiation modulates vascular endothelial growth factor (VEGF) expression through multiple mitogen activated protein kinase dependent pathways Oncogene 20 2001 3266 3280
21. D. Raben, B. Helfrich, D.C. Chan The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer Clin Cancer Res 11 2005 795 805
22. L. Milas, K. Mason, N. Hunter In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody Clin Cancer Res 6 2000 701 708
23. C. Bianco, G. Tortora, R. Bianco Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa) Clin Cancer Res 8 2002 3250 3258
24. S.B. Maddineni, V.K. Sangar, J.H. Hendry Differential radiosensitisation by ZD1839 (Iressa), a highly selective epidermal growth factor receptor tyrosine kinase inhibitor in two related bladder cancer cell lines Br J Cancer 92 2005 125 130
25. J.A. Bonner, J. Giralt, P.M. Harari Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck A phase III study of high dose radiation therapy with or without cetuximab [Abstract] Proc Am Soc Clin Oncol 22 Suppl. 2004 5507
26. T. Hoang, S.-M. Huang, E. Armstrong Augmentation of radiation response with the VEGFR-tyrosine kinase inhibitor ZD6474 [Abstract] Proc Am Assoc Cancer Res 45 2004 955
27. K.J. Williams, B.A. Telfer, S. Brave ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy Schedule-dependent enhancement of antitumor activity Clin Cancer Res 10 2004 8587 8593
28. D.L. Gustafson, A.L. Merz, J.A. Zirrolli Impact of scheduling on combined ZD6474 and radiotherapy in head and neck tumor xenografts [Abstract] Eur J Cancer Suppl 2 2004 45 46
29. K. Shibuya, R. Komaki, W. Wu Targeted therapy against VEGFR and EGFR signaling with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic mouse model of human non-small-cell lung cancer [Abstract] Int J Radiat Oncol Biol Phys 60 Suppl. 2004 S145 S146
30. D. Siemann, W. Shi The VEGFR2 tyrosine kinase inhibitor, ZD6474, enhances the antitumor effect of radiation [Abstract] Eur J Cancer Suppl 2 2004 49
31. V. Damiano, D. Melisi, C. Bianco Cooperative anti-tumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma Clin Cancer Res 11 2005 5639 5644
32. S.N. Holden, S.G. Eckhardt, R. Basser Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signalling, in patients with solid, malignant tumors Ann Oncol 16 2005 1391 1397
33. H. Minami, H. Ebi, M. Tahara A Phase I study of an oral VEGF receptor tyrosine kinase inhibitor ZD6474, in Japanese patients with solid tumors [Abstract] Proc Am Soc Clin Oncol 22 2003 194
34. J.A. Zirrolli, E.L. Bradshaw, M.E. Long Rapid and sensitive LC/MS/MS analysis of the novel tyrosine kinase inhibitor ZD6474 in mouse plasma and tissues J Pharm Biomed Anal 39 2005 705 711
35. F. Ciardiello, R. Bianco, R. Caputo Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy Clin Cancer Res 10 2004 784 793
36. D.W. Siemann, W. Shi Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors Int J Radiat Oncol Biol Phys 60 2004 1233 1240
37. H. Hurwitz, L. Fehrenbacher, W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342
38. C.G. Willett, Y. Boucher, E. di Tomaso Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Nat Med 10 2004 145 147